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Abstract  
This paper provides an overview of the current and near-future applications of Artificial Intelligence 
(AI) in Medicine and Health Care and presents a classification according to their ethical and societal 
aspects, potential benefits and pitfalls, and issues that can be considered controversial and are not 
deeply discussed in the literature.  
This work is based on an analysis of the state of the art of research and technology, including existing 
software, personal monitoring devices, genetic tests and editing tools, personalized digital models, 
online platforms, augmented reality devices, and surgical and companion robotics.  
Motivated by our review, we present and describe the notion of “extended personalized medicine”, 
we then review existing applications of AI in medicine and healthcare and explore the public 
perception of medical AI systems, and how they show, simultaneously, extraordinary opportunities 
and drawbacks that even question fundamental medical concepts. Many of these topics coincide 
with urgent priorities recently defined by the World Health Organization for the coming decade. In 
addition, we study the transformations of the roles of doctors and patients in an age of ubiquitous 
information, identify the risk of a division of Medicine into “fake-based”, “patient-generated”, and 
“scientifically tailored”, and draw the attention of some aspects that need further thorough analysis 
and public debate. 
 
Introduction  
Artificial Intelligence (AI) is a new realm of science and technology. It already affects many human 
activities at all societal levels, from individuals to social groups, corporations and nations. AI is 
expanding rapidly, worldwide, in almost every industrial, economical and societal sector, from 
information technologies to commerce, manufacturing, space, remote sensing, security and 
defense, transport and vehicles and, since the beginning of the XXI century, it is effectively entering 
into Medicine and Health Care1,2. 
The fast and powerful evolution of AI is fostered by many factors. Among them,  
 the availability of powerful and cost-effective computing (processing) tools, hardware (e.g. 
graphics processing units), software and applications, –even in consumer-grade personal 
computers and mobile devices– and of large (big) data sets, with many different types and 
formats of information, both in online and cloud platforms and generated in real time by 
user wearables and the internet-of-things (IoT),  
 the expansion of open source coding resources and online communities of users and 
practitioners sharing resources, expertise (know-how), and experience, and  
 the combination of computer processing with other technologies such as photonics (merging 
of applied optics and electronics) and human-machine interfaces. 
Recent advances in AI systems in Medicine and Health Care present extraordinary opportunities, –
particularly in areas of such deep social interest as oncology3– together with significant questions4 
and drawbacks5–7, calling for a close consideration of their implementation8 and how they affect –
and can even change– basic definitions in the medical context9–11.  
This study provides a review of existing and near-future applications of AI in this particular sector 
from the point of view of their potential benefits and pitfalls, ethical and social impact. We also 
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identify a set of controversial issues that are not deeply discussed in the literature and should be 
further researched.   
Notably, many of the topics presented in this work coincide with six of the thirteen urgent priorities 
recently defined by the World Health Organization (WHO) for the coming decade12. These coinciding 
priorities explicitly include: “Harnessing new technologies”, “Earning public trust”, “Protecting 
people from dangerous products”, “Making health care fairer”, “Expanding access to medicines”, 
and “Preparing for epidemics”. Within the specific priority of “Harnessing new technologies”, the 
WHO defines the challenge as “New technologies are revolutionizing our ability to prevent, diagnose 
and treat many diseases. Genome editing, synthetic biology and digital health technologies such as 
artificial intelligence can solve many problems, but also raise new questions and challenges for 
monitoring and regulation. Without a deeper understanding of their ethical and social implications, 
these new technologies, which include the capacity to create new organisms, could harm the people 
they are intended to help”. 
This work is based on an exhaustive literature review of existing scientific publications and technical 
publications, including software packages, personal monitoring devices, genetic tests and editing 
tools, personalized digital models, online platforms, augmented reality devices, and surgical and 
companion robotics13. This review covered 588 references, most of them from 2016-2019 but 
intended to be dynamically updated, including standard scientific and academic platforms such as 
MEDLINE, Current Contents and PubMed plus product descriptions and internet and press articles 
of well-recognized sources which are relevant for the topic. From this review, we summarize here 
our main findings, discussion points and conclusions, supported by 107 representative references. 
 
“Tech-savvy”: From early pioneers in imaging and surgery to robotics and online platforms. 
In Medicine and Health Care, AI has evolved from computer programs to support the analysis of 
medical images to its integration in almost every clinical14 and organizational area15. Radiology16 was 
at the forefront of this transformation, together with different branches of surgery using augmented 
reality devices17 and surgical robots18. They were quickly followed by other image-based specialties 
(e.g. pathology19, dermatology20, ophtalmology21) and, more recently, by virtually all areas of 
Medicine and Health Care, from general practitioners22 to emergency departments23,  
epidemiology24, and disease management25. Systems for “computer-aided diagnosis” have 
expanded to include online assistants (e.g. app, chatbots) –both for very specific medical areas (e.g. 
oncology26, predicting the response to treatments27) and for the general public28–, and “clinical 
robots” now include “social companions” for hospitalized person, particularly children29 and the 
elderly30. In addition, wearables and IoT devices allow for real-time monitoring of physiological 
information, even at home31, and, integrated with medical and social-media data, can trigger 
clinically related automated interventions (from suicide prevention calls to police32 to medication 
delivery33).   
Concerned –even healthy– citizens can now order direct-to-consumer genetic tests among many 
thousands in the market34. New tools for big data modeling, analysis, and visualization are also 
expanding, and provide substantial, transforming improvements in clinical pathways35, from the 
generation of “digital twins”36 of individual patients to self-management of treatments37. There are 
even online, crowd shared platforms for such high-end applications as radiotherapy38. Many 
management aspects related to health economy (e.g. increased efficiency, quality control, fraud 
reduction) and policy39 also benefit from the new AI mediated tools. They even offer new hopes of 
improvements in health for environments with reduced resources40 and in developing regions41. 
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However, technical challenges42–44 and ethical concerns45–47 remain, and new important questions 
arise. 
 
Classification of the applications of Artificial Intelligence in Medicine and Health Care. 
In Figure 1 we propose a graded classification of AI and AI-mediated applications in Medicine and 
Health Care according to their beneficial vs detrimental character as recognized in the reviewed 
literature. For each of these applications, we report the technology, the specific implementations 
behind and their level of availability according to published references. On the one side of the 
spectrum of social impact we consider applications that have been shown to be beneficial to support 
clinical decision making, while on the other side we place applications that are widely agreed to be 
harmful.  
In Figure 1 we also propose a (new) scale named "Technology Availability Level" (TAL) which gives a 
qualitative description of the degree of availability of a technology, in a numerical scale from 0 
(unknown) to 9 (available for the general public). The TAL scale is similar in format (and related) to 
the standard "Technology Readiness Levels" (TRL) but, as mentioned, it is based on published 
references (in scientific and academic literature, industrial or corporate reports, and general media 
citing sources considered to be reliable according to standards). It is important to consider that 
"availability" is not necessarily equivalent to "readiness levels" due to such factors as disclosure 
according to industrial, proprietary and/or government strategies, and that the TAL scale does not 
evaluate either the fulfillment of regulatory processes. The values defined for the TAL scale are the 
following: 
TAL 0. Unknown status. Not considered feasible according to references. 
TAL 1. Unknown status. Considered feasible according to related, indirect references. 
TAL 2. General/basic idea publicly proposed. 
TAL 3. Calls for public funding of R&D open. 
TAL 4. Results of academic/partial projects disclosed. 
TAL 5. Early design of product disclosed. 
TAL 6. Operational prototype/'first case' disclosed. 
TAL 7. Products disclosed but not available. 
TAL 8. Available for restricted (e.g. professional) users. 
TAL 9. Available for the public. 
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Figure 1. Proposal of classification of artificial intelligence (AI) and AI-mediated applications in 
Medicine and Health Care according to their beneficial vs detrimental character. SW = software, AR 
= augmented reality, VR = virtual reality, IoT = internet of things. TAL = Technology Availability Level 
(see details of values in the text). 
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In Figure 2 we complement this classification with an analysis of the main related (ethical and 
social) aspects of AI technologies by defining three partially overlapping sets:  
1. In the first group we include those topics commonly under analysis as raised by other AI 
application domains (e.g. social networks, online commerce, automation in factories, 
autonomous vehicles) such as data use and sharing48,49, privacy50, security, and 
annonymization51. 
2. In the second group, we consider topics –some of which are also under analysis in other 
sectors– which are of particular relevance in our context. Among them, the proper training 
of AI systems to avoid bias52 and assure fairness and equity53, the difficulties to explain the 
“reasoning process” of complex systems54, the lack of updated evaluation protocols55,56 and 
regulatory standards57,58, the legal aspects of liability and malfunction59, and the 
vulnerability of medical information under adversarial attacks60. And, of course, the question 
of whether (or not) harnessing AI systems under human control61.  
3. Finally, in the third group we place some aspects barely or not included in the reviewed 
literature. They mainly relate to the potential dual use of certain technologies, from limit-
defying research about human control, ‘biological robots’, human-animals hybrids and 
biohacking to weaponization and bioterrorism. They will be discussed –with examples from 
neuroscience and gene editing– in a later section. 
It is important to note that many AI systems and AI-mediated applications show an intrinsic “mix” 
of positive, negative, and controversial aspects depending on their specific implementations, and 
that, according to published information, their readiness levels vary from commercially available to 
very early, conceptual designs.  
To our knowledge, this is the first attempt to provide an exhaustive list of AI systems and 
applications in Medicine and Health Care taking into account their potential benefits and pitfalls. 
However, it is not intended to define an “absolute” scale of “goodness” or “badness”, as many 
technologies (e.g. gene editing, neuroprostheses) are not necessarily “positive” or “negative”, and 
others may certainly be difficult to categorize.  
Even the scientific and ethical criteria for such analysis need a review, and new questions arise. The 
methods used to evaluate the performance of medical products and treatments are based on 
averages over population groups, while we now consider extremely personalized approaches, to the 
genetic structure of each individual. How can those treatments be rigorously tested? Which are the 
time and cost required to find “enough cases” to “generate scientific evidence”? In addition, how 
should AI systems be benchmarked? Should they be compared to a (possibly error-prone) human 
doctor or “against” another “machine”? Common ethical guidelines for the evaluation of 
technologies mostly date from the pre-digital era. Which should be the figures of merit to consider? 
Which are the roles of the public and the policy makers? 
The goal of the classification proposed in these figures is to draw attention to the need of a careful, 
thorough analysis and as the basis for our discussion below, with a focus on those issues hardly 
addressed in the current literature. As mentioned, it is particularly important that many of these 
topics have been explicitly defined as “urgent priorities for the coming decade” by the WHO12 at the 
beginning of 2020. 
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Figure 2. Ethical and social aspects of artificial intelligence (AI) and AI-mediated technologies in 
Medicine and Health Care in three groups (G1, G2, and G3). Some key relevant questions, 
controversies, significant, and conflicting issues are outlined for each aspect. 
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“Extended Personalized Medicine”. 
The original goal of Personalized Medicine is to exploit very specific biological (genetic) features of 
individuals for tailored diagnosis and treatment62. Decoding the genome of each patient represents 
a very significant change from the existing model of averaged analysis of populations to an 
extremely individualized approach63, for treating disease –in a new paradigm defined as “precision 
medicine”64– but also to promote wellness65 and healthy, personalized lifestyles.  
However, although not explicitly formulated in the literature, we consider that the underlying 
principle of Personalized Medicine can be further expanded. It can include other properties whose 
particular values or structures –even their spatial distribution and time evolution in the human 
body– may be significantly different for any single individual, in different clinical situations, at every 
moment of life and, possibly in strong relationship to each other. Such additional features form the 
new concept of “Extended Personalized Medicine” and they may come from  
 “known sources” from the “basic sciences” of physics (e.g. bioelectromagnetic fields and 
signals, biomechanical magnitudes and properties, hydrodynamic parameters of the 
circulation of any fluid in the body), chemistry (concentrations of ions, molecules), and 
biology (metabolites),  
 “not yet known” origins. This concept refers to the potential characterization of brain 
processing schemes, connections, and functions whose details still remain veiled for science, 
 demographic data, extracted from conventional databases, 
 data about psychological and emotional status, extracted indirectly from the individual 
activity in social networks. 
 social data, including those about societal structures (family, groups providing psychological, 
emotional support), and cultural and religious beliefs which may influence health-related 
issues, such as restrictions on types of food or sexual activity, provided by the user or mined 
from social networks,  
 “lifestyle parameters” (sleep hours, stress, physical activity, food ingest) easily accessible 
through apps, wearables, and IoT, 
 values of environmental and physical geography conditions (weather, contamination) 
transmitted by multiple platforms,  
 sensors evaluating mood through face and gesture recognition, changes in cardiac rhythms, 
perspiration, and breathing patterns when receiving certain visual or auditory stimuli. They 
may be biometrics readers in smartphones, domotic environments, and wearables, 
Many sources of such data are already available. They include “standard” clinical scores and 
evaluations (imaging scans, analytics), results of genetic and “omics” (genomics, metabolomics, 
proteomics) tests, and medical knowledge from publications and references, but also data from 
social networks66 and from personal, IoT, and home sensors67. Together with potential benefits68, 
such as predicting individual response to treatments69, this “accumulation” of personal, intimate 
information also presents very high risks regarding ownership, security and privacy.  
From a technical point of view, the combination of varied heterogeneous sources requires the use 
of advanced AI-mediated tools for merging, processing, and analyzing multiple data layers –
extracting useful information– and to operate the devices of augmented and virtual reality for the 
(very much needed) interactive navigation and visualization. 
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Replacement or enhancement: Do we need a doctor? 
AI systems pose important conceptual challenges for physicians. The most relevant is the debate 
between AI-replaced or AI-enhanced doctors70,71.  
As in any other sector, the appearance of (even partially) automated systems produces deep 
professional transformations, as some jobs will be lost and new ones will arise. Current systems for 
clinical applications may be mostly considered as “weak AI” that is, they can succeed at “narrow” 
tasks and be useful helping human physicians in tedious, repetitive activities (e.g. finding elements 
or segmenting organs or structures in images). As mentioned, medical specialties dealing with visual 
analysis of images have started to experiment substantial changes through such “aids”. Bottom-line 
is that computerized systems can process many, many more images than any human operator can, 
without fatigue and time constraints, and –if properly trained– with even better results. AI systems 
also show very good performance in the recognition of natural language and written texts, which in 
turn opens the way to extracting information –for systems to learn– from many available sources 
(e.g. clinical records) which are not usually available in structured, useful formats. But in general, 
medical AI systems lack the ability to “interpret” the context and “generate” the most distinctive 
human features (creativity, emotions), and cannot be considered (yet) as “strong” or ”general” AI72. 
Although many questions remain73, AI systems can enhance many aspects of doctor’s tasks and 
those professionals choosing not to use them will be outdated. 
The availability of massive amounts of data conveying very different types of information of each 
individual patient also requires new professional profiles –not necessarily physicians– to explore 
and extract the most useful items for diagnosis and treatment. Genetic counselors are already 
joining clinical teams to help (patients but also professionals) in understanding the complex gene-
related information74. The addition of novel sources of data –in the foreseeable paradigm of 
“expanded personalized medicine”– will likely require some other profiles of “medical data 
scientist” for specialized advice for physicians and patients. 
Key intangible qualities.  
Healthcare is not just an intellectual interaction but highly social, especially relevant in situations of 
vital relevance (e.g. decisions with effects on life quality, palliative care, euthanasia). There are many 
different views on trust, empathy, and the humanization of care, and how they can be affected by 
the new reality of automated systems, from the reduction of medical errors to the possibility of AI-
systems helping humans to take difficult decisions, to the design of better doctor-AI and patient-AI 
interaction strategies75,76. Proponents of AI-enhanced human doctors see the integration of new 
tools as a powerful way to regain human aspects of the relationship between the doctor and the 
patient77 but the real results are yet unknown78. 
A key issue in of the greatest importance in all AI-related areas is that of increasingly autonomous 
systems79. In the medical and surgical fields, their capabilities may include the decision about human 
lives and, if they ever become available, which would be their ethical guidelines? For many people, 
this scenario may seem unreal, but there is a current debate about a topic that shares some of the 
arguments and positions, namely that about lethal autonomous weapons systems. Such devices 
have already made their way to the public –even to be discussed at the United Nations80 – as this 
type of research has been (at least) partially disclosed and early systems begin to be displayed. Their 
objectives are clearly the opposite of medical devices, and the popular name of “killer robots” may 
ward it off from being included in medical literature, but the fundamental idea to discuss is the 
same: will “a machine” take the ultimate decision to keep or end a human life? 
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A new situation: patients take the lead. 
The evolution of individual behavior as related to Medicine and Health Care presents a novel array 
of many advantages, pitfalls, and un-addressed concerns. The overall access to many types of data 
has already had an important effect in the relationship between the patient and the doctor, namely 
the reduction of the “asymmetry in information” between them and the evolution towards a 
“patient-centric” model81. This new situation started with the generalized availability of information 
in online platforms. Suddenly, patients could ask “the Internet Doctor” about anything82, from 
symptoms to the side effects of treatments to advices for healthy lifestyle, and then visit the real 
physician’s office with a list of “informed” questions, requests, and even complaints. In the following 
years, it has become evident that there is no “a priory” guarantee of the quality –even the certainty– 
of the information found on internet searches. Very valuable resources are mixed with completely 
erroneous –even maliciously misleading– material and a certain level of knowledge is required to 
find and understand the information of real interest for any case. To evaluate the clinical situation 
of a patient and potential treatment options there is a clear need of the “integrated analysis”, of 
the “global vision” provided by a qualified, trained, real doctor.  
The evolution of technology is expanding AI systems, starting from “basic” –but very effective– 
symptom’s checkers and on the road to increasingly autonomous “digital doctors”. AI-supported, 
even shared-decisions –with non-human systems– and patient involvement shape substantial 
changes. However, a very dangerous division of “Medicine” in three sub-types may therefore take 
place:  
i) “Fake-based” Medicine. Based on (unfounded, unconfirmed) rumors and “fake news”, this type of 
“pseudo-medicine” may present “ancient, natural knowledge” as opposed to scientific, evidence-
based medicine, considered to be under malicious control by corporations, academia, institutions, 
and governments. Even rejecting technology, it may easily take benefit from the expanding ability 
and multiplying power of online platforms and AI-mediated tools (including chatbots, interactive 
apps, and communities of followers) for dissemination of wrongful information. This type of 
misinformation –such as in the case of “anti-vaccine” groups– is increasing83, being used to discredit 
“conventional” therapeutic approaches and to promote that patients abandon treatments and 
follow-up by physicians, with very serious potential consequences –even with the risk of death– 
both for the individuals affected and their surrounding environments. In addition, “digital health 
scammers” can benefit from available data-driven personalized AI tools to offer clinical advices and 
treatment options to vulnerable population with no guarantee or reliability.   
ii) “Patient-generated” Medicine deriving from the growing online availability of many (both correct 
and unsupervised, unreliable) sources of medical information, even of platforms and apps supposed 
to evaluate and interpret the results of (almost any) type of analysis, including imaging scans and 
genetic tests.  
Although a “better informed patient” is a positive consequence of the availability of information, 
individual-ordered analysis and diagnosis lack the (fundamental) “global vision” that the doctor can 
offer to the patient and the (crucial) trained skills required for proper understanding of test results 
and deciding subsequent steps. Any person, even medically illiterate, without any medical education 
or training, may have –through AI-mediated tools– immediate, unlimited access to a trove of 
information that may be considered correct and related to a disease or health issue. Resulting 
decisions may then –very probably– bring inadequate, even damaging, consequences, without the 
potential help or support from any established medical institution. 
iii) “Scientifically tailored” Medicine is the type of medical science that evolves from research into 
extended personalized medicine. For the patients, the critical decision would probably be the 
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selection of the human doctor –perhaps the AI-system– to lead the team of “conventional” (clinical) 
and “new” (e.g. genetic counselors, medical data scientists) professional profiles required to 
correctly integrate the multiple, extensive sources of information to establish the diagnosis and 
define the corresponding treatment and monitoring strategies.  
Affordability and inequality. 
Global figures and market of AI in Medicine and Health Care forecast very relevant, positive impact 
for the coming years. However, the economic analysis must include the ethical and social points 
related to health systems, the industries and the patients84. It is important to note that the cost of 
decoding a human genome is substantially low –in the order of a few hundred euros– but the prices 
of some of AI-mediated treatments, such as certain personalized drugs, may reach “impossible” 
figures, even in the order of millions of euros per case. This steep step is due to the difficulties of 
individually tailoring drug molecules to the specific genome of an individual. New models of health 
coverage, insurance, and affordability may be needed85 as such clinically excellent technologies pose 
a clear risk of evolving into a significant increasing factor of inequality for most people. 
Barely mentioned but not science fiction any more: the dual use of technology. 
We address now some aspects and applications of AI-mediated technologies that can be very 
controversial and that, even though society is not currently addressing, are advancing at a fast, 
uncontrolled, unsupervised pace. Most developments simultaneously present the potential of very 
positive, disruptive improvements with deeply disturbing, ethically questionable –even very 
negative– outcomes. 
i) Decoding and interacting with brain signals: from hope to limitations on free will. 
Neuroscience is one of the scientific realms in which the advent of technological advances from 
other disciplines is fostering an extraordinary development. Main contributions come from merging 
AI, photonics and engineering. Neuroscience also encompasses neurosurgery and neurology with 
other clinical areas (pharmacology, psychology) and related sciences (biology and genetics, 
biochemistry). With significant ethical challenges86, advances point towards progressively non-
invasive, remote reading and decoding the complex signals of the brain and the design of advanced 
man-machine interfaces87, with simultaneous health-related88 and military applications89. 
On an extraordinarily beneficial approach, this knowledge opens the way to the human nervous 
system –already starting to allow for interactive control of innovative, active prostheses–, which 
offer a great hope for many persons with severely disabling conditions, and many potential 
industrial applications. There are very strongly funded projects, e.g. the European Human Brain 
Project90 and the USA Brain Initiative91, oriented to “the positive aspects” of neuroscience. However, 
this knowledge also relates to very controversial paths, e.g. the potential ability to “read the mind”, 
and its eventual combination with different types of neural stimulation and interaction with brain 
signals, which, in turn, might lead to undesired forms of manipulation (lack of free will) and human 
control.  
ii) Gene editing: From tailored treatments to unexpected effects, self-experimentation, human-
animal embryos, biohacking and bioterrorism. 
A clear example of a controversial, AI-mediated area is human gene editing. The possibility of 
altering –and substituting– definite fragments of the genetic (deoxyribonucleic acid, DNA) chain of 
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human cells is a challenging task –which requires AI tools to reach the required precision– with many 
potential applications.  
Genetically modified organisms are becoming common in agriculture and farming to increase 
productivity and reduce the impact of plagues and diseases, and the subject of relatively active 
social debates in some countries. In 2018, human gene editing –and the ethical doubts– made to 
the headlines as the first two “engineered twins” were born in China92. From a “positive approach”, 
the “correction” of “wrong”, mutated genes to avoid severe diseases, important questions 
immediately arise: Does it really work? In terms of impact on the human genetic heritage, at what 
cost? It has already been published that these two babies present unknown defects and 
unpredictable future development. Then, is it ethical to design “experimental human beings”? What 
will happen if those people become adults and procreate? Will there be any limits in the genes to 
be modified? That is, if the procedure is technically feasible, will anyone engineer some types of 
“super-humans”? Should there be some type of oversight of this research? Most of these questions 
are common to other controversial areas of AI applications, have barely been asked and do not have 
any clear answer yet.  
Another troublesome application of gene editing technology is the generation of human-animal 
embryos. They are purportedly created with the goal of solving the critical scarcity of organs for 
transplant and under the self-imposed limits of their creators of developing only required organs in 
genetically modified, not viable, embryos or not letting new beings grow beyond certain thresholds. 
Perhaps this type of research might even lead to growing “replacement organs” without the need 
of a “hosting embryo”. But if some types of them might eventually have the potential to develop 
into “adult beings”, should they be allowed? Would they be considered “full or partially” humans 
subject to rights? In ancient mythology, these types of creatures were called “chimera” and their 
existence was limited to the godly heavens and the infra-world of hell. But in 2017, early 
experiments of interspecies (human-pig) cell growing were announced, in 2018 first steps in a 
human-sheep embryo was disclosed, and in 2019 Japan formally authorized this type of research 
under certain restrictions93. A ratcheting up in this field is given by the recently disclosed 
development of a prototype of a ‘living machine’ –also considered to be a ‘biological robot’ 
(‘biobot’)– based on animal cells94, and the search for artificial forms of life for military 
applications95.  
With a relatively small laboratory and the proper knowledge and tools, gene editing can be achieved. 
There are some reports of persons undergoing self-experimentation, who modify their DNA and re-
introduce it in their bodies, in a novel type of “citizen science approach” named biohacking96. Their 
intended purpose is generally to obtain “enhanced capabilities” but this type of research also 
presents a potential interest for the health market97. However, the availability of certain AI-
mediated tools (hardware, software, and datasets) may also open the way to malicious forms of 
biohacking. Gene editing combined with such use of AI technologies present a worrying, very soft 
boundary to weaponization and bioterrorism98. Genetically modified organisms can be very difficult 
to detect and track. They might be even stored and transported as altered cells in a carrier person 
targeting specific individuals or populations. 
 
Informed public debate on setting (or no) limits to research and development. 
AI in Medicine and Health Care is no longer an isolated discipline but laying at the intersection of 
medicine, sciences and engineering, and social disciplines (ethics, philosophy). It already has deep 
influences on many issues related to human health and wellbeing at many different scales and the 
consequences of the wide range of ongoing developments may affect basic concepts covered by 
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international regulations, from the Hippocratic Oath in Medicine to the fundamentals of free will as 
declared in the Bill of Human Rights. 
In addition, AI in Medicine and Health Care is a very dynamic area, inevitably linked with (the very 
fast) evolution of other technologies, mainly those related to computers, photonics and different 
branches of engineering. It has many positives perspectives together with controversial and clearly 
negative aspects. In some applications, AI and AI-mediated tools even evolve to questioning the 
definition and the limits of life. But which is the public view about such research99,100? Most scientific 
and technological initiatives receive public funds and society needs informed decisions and rigorous 
information to general and professional audiences, as in other areas of AI101–103. Some specific 
guidelines begin to appear for big data and digital health104,105, and even a “do no harm” approach 
has been formulated recently106, but most of the applications of AI in Medicine and Health Care 
shown in Figure 1 –namely, those that present the most conflicting aspects– are neither mentioned 
nor being analyzed yet. As mentioned, some of these topics have recently defined as urgent 
priorities for the coming decade by the WHO12. 
However, the required study is not easy. The categorization of technologies as “good” or “bad” is 
strongly dependent on many factors, in which subjective, personal and societal values play an 
essential role. While it seems evident that objective, professional criteria should be defined for 
proper judgement, the extraordinary impact of Medicine and Health Care in human beings and 
society transcends a “technical evaluation” and requires to take into consideration cultural, ethical 
and social criteria as well. To increase the complexity of the analysis, the acceptance and potential 
expansion of the applications of AI relate to multifaceted balances of welfare effects and economic, 
geographical –even political– aspects, but they are essentially linked to the personal, intangible 
qualities –based on trust– that configure the (current) relationship of doctor and patient. 
At the “person scale”, important goals of public, regulatory institutions should be to allow for the 
(very challenging) generalized access of the population to the beneficial results of “scientifically 
tailored” Medicine while protecting citizens from falling into the risks of “pseudo-medicine” (“fake-
based” and “patient-generated”) and into becoming victims of “digital health scammers”. To 
achieve such objectives, the availability of fair, trustworthy, contrasted information open to public 
access is essential.  
Moreover, at the “institutional scales”, we propose to follow the example of another “controversial” 
research area, namely that of nuclear technology, which fosters beneficial applications –as in 
radiation therapy against cancer– while simultaneously restricting negative developments –as 
weapons of massive destruction–. Key aspects of AI and AI-mediated technologies related to the 
most controversial topics could be identified and have their access and availability restricted only to 
qualified users, following similar protocols and procedures to those used to control nuclear and 
radioactive sources, devices, and design specifications. Definite efforts are required to thoroughly 
study each element included in the proposed classification and the new societal and ethical 
challenges that they generate.  
 
Conclusions. 
The range of applications of AI and AI-mediated technologies in Medicine and Health Care is vast 
and rapidly increasing, with many powerful potential (positive and negative) results, which may 
affect the human being and society at all scales. Most of the questions collected in this review 
remain challenging as their answers are not yet clear at this time, but our goal is to open the way 
for a multidisciplinary, public discussion of the raised issues to define the principles, ethical and 
societal guidelines –and potential boundaries– on this matter.  
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